Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$93.13 USD

93.13
25,247,523

+1.13 (1.23%)

Updated Jun 24, 2022 04:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.75%
2Buy18.15%
3Hold9.70%
4Sell5.35%
5Strong Sell2.45%
S&P50010.91%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Large Cap Pharmaceuticals

Trades from $1

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates

The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).

Merck's (MRK) Pneumococcal Vaccine Gets FDA Nod for Kids

Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

Merck (MRK) Gains As Market Dips: What You Should Know

Merck (MRK) closed the most recent trading day at $89.16, moving +1.28% from the previous trading session.

Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs

Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma, this August.

Seagen (SGEN) Stock Up on Rumors of Acquisition by Merck

Shares of Seagen (SGEN) rise after rumors of a buyout by Merck hit the market. However, a deal is not imminent at the moment.

The Zacks Analyst Blog Highlights Lilly, Merck, Roche, Pfizer and Moderna

Lilly, Merck, Roche, Pfizer and Moderna have been included in this Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Panel Nod for PFE, MRNA Young Kids' COVID Jabs & More

FDA panel recommends the use of PFE, MRNA COVID vaccine in kids under five. LLY's Alzheimer's candidate fails to show clinical benefit in study. FDA approves expanded use of LLY's Olumiant.

Merck (MRK) Gains But Lags Market: What You Should Know

Merck (MRK) closed the most recent trading day at $84.63, moving +0.15% from the previous trading session.

Pfizer (PFE) COVID Pill Ineffective in Standard Risk Patients

Pfizer (PFE) stops enrolling patients in a phase II/III study evaluating its COVID pill in standard-risk population after new data from this study showed that it is not all statistically significant.

Merck (MRK) Keytruda Adjuvant Lung Cancer sBLA Accepted by FDA

The FDA is expected to give its decision on Merck's (MRK) Keytruda sBLA for adjuvant stage IB-IIIA NSCLC, following complete surgical resection, on Jan 29, 2023.

Bristol Myers (BMY) Up 20.4% YTD: Will the Momentum Continue?

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.

Merck (MRK) Stock Moves -1.65%: What You Should Know

Merck (MRK) closed the most recent trading day at $88, moving -1.65% from the previous trading session.

Roche (RHHBY) Gets EU Nod for Lunsumio, Tecentriq Label Expansion

Roche (RHHBY) obtains EU approval for Lunsumio for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) and label expansion of Tecentriq.

Bristol Myers (BMY) to Acquire Turning Point, Withdraws sBLA

Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.

Merck (MRK) Stock Moves -0.1%: What You Should Know

In the latest trading session, Merck (MRK) closed at $89.91, marking a -0.1% move from the previous day.

Regeneron (REGN) to Buy Sanofi's Stake in Libtayo, Stock Down

Regeneron (REGN) will obtain global rights to Libtayo from Sanofi in exchange for an upfront payment of $900 million and royalties.

The Zacks Analyst Blog Highlights AstraZeneca, Merck, Roche, J&J, and Pfizer

AstraZeneca, Merck, Roche, J&J, and Pfizer are part of Zacks top Analyst Blog

Bristol Myers' (BMY) Opdivo Combos Get FDA Nod for ESCC

Bristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Iovance (IOVA) Down After Announcing Data From Melanoma Study

Results from a cohort of the phase II study evaluating Iovance's (IOVA) melanoma candidate were not as superior as data from another cohort of the same study.

Mirati (MRTX) Down 23% on Mixed Data From Lung Cancer Study

Mirati (MRTX) posts positive data from a phase II study evaluating its lung cancer candidate adagrasib. However, the drug caused side-effects in a large number of study participants.

Exelixis (EXEL) Announces Results From Phase II HNSCC Study

Exelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with recurrent or metastatic head and neck squamous cell carcinoma meets primary goal.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids

European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.

Merck (MRK) Keytruda Gets EU Nod for Expanded Breast Cancer Use

The European Commission approves Merck's (MRK) Keytruda for high-risk early-stage TNBC, which expands its eligible patient population.

Seagen (SGEN) Posts Positive Data from New Study on Tukysa

Seagen (SGEN) reports favorable data on the pivotal phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin for treating HER2-positive metastatic colorectal cancer.